Evidence map›Paper›PMID 28185203›Full record

ArticleInternational journal of hematology2017

HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.

Masatoshi Takagi, Yasuyoshi Ishiwata, Yuki Aoki, Satoshi Miyamoto, Akihiro Hoshino, Kazuaki Matsumoto, Akira Nishimura, Mari Tanaka, Masakatsu Yanagimachi, Noriko Mitsuiki and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Masatoshi TakagiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan. m.takagi.ped@tmd.ac.jp.ORCID http://orcid.org/0000-0002-7580-9184
Yasuyoshi IshiwataDepartment of Hospital Pharmacy, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan.
Yuki AokiDepartment of Pediatric Oncology, National Cancer Research Center, Tsukiji 5-1-1, Chuo-ku, Tokyo, Japan.
Satoshi MiyamotoDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Akihiro HoshinoDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Kazuaki MatsumotoDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Akira NishimuraDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Mari TanakaDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Masakatsu YanagimachiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Noriko MitsuikiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Kohsuke ImaiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Hirokazu KaneganeDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Michiko KajiwaraDepartment of Transfusion Medicine, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan.
Kanako TakikawaDepartment of Hospital Pharmacy, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan.
Tsukasa MaeDepartment of Hospital Pharmacy, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan.
Osamu TomitaDepartment of Pediatrics and Adolescent Medicine, Juntendo University, School of Medicine, Yushima 2-1-1, Bunkyo-ku, Tokyo, Japan.
Junya FujimuraDepartment of Pediatrics and Adolescent Medicine, Juntendo University, School of Medicine, Yushima 2-1-1, Bunkyo-ku, Tokyo, Japan.
Masato YasuharaDepartment of Pharmacokinetics and Pharmacodynamics, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bunkyo-ku, Tokyo, Japan.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Okura 2-10-1, Setagaya-ku, Tokyo, Japan.
Shuki MizutaniDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Tomohiro MorioDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University (TMDU), Yushima 1-5-45, Bukyo-ku, Tokyo, 113-8510, Japan.
Tokyo Medical and Dental University · JPJuntendo University · JPNational Center For Child Health and Development · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration-time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia. The target AUC for two patients who had already received multiple transplantations was 3600 and 4000 μmol min/L, and that for the patient with Down's syndrome was 3000 μmol min/L. Regimen-related toxicity was well tolerated in all cases. All three maintained cytological remission throughout the follow-up period (between 31 and 167 weeks). Thus, haploidentical HCT conditioning with clofarabine and target AUC-based busulfan adjustment may be a preferable option for children with recurrent or refractory pediatric leukemia.

Indexed as

HaploidyHematopoietic Stem Cell TransplantationTransplantation ConditioningAdenine NucleotidesArabinonucleosidesBusulfanChildClofarabineFemaleFollow-Up StudiesHLA AntigensHumansLeukemiaMaleRecurrenceRemission InductionAdenine NucleotidesArabinonucleosidesBusulfanClofarabineHLA AntigensBusulfanClofarabineHaploidentical hematopoietic cell transplantationPediatric refractory leukemia

Identifiers

PMID28185203
OpenAlexW2587455657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.